Aaron Joseph Henry Pendola

Aaron is a graduate of Tufts University. As an experienced entrepreneur and federal contractor, he brings a dynamic background in biomedical information technology (IT), public health, pharmaceutical/nutraceutical/biologics R&D and regulatory compliance to his role on the Board at the Fenbendazole Foundation. With more than a decade of experience across federal research and regulatory agencies and biomedical mission-driven private ventures, Aaron is committed to advancing credible, community-centered research on fenbendazole and its potential applications in cancer and infectious disease into a government-regulated and a popularly-accepted movement amongst the medical mainstream.

Aaron’s journey in drug discovery began by providing technical, scientific, and professional support services to the US Department of Health and Human Services (HHS), where he supported major government research initiatives focused on pharmaceutical and biologics product R&D in the fields of oncology, virology, and translational science. As a government contract business developer, grant writer, and program manager, Aaron has helped manage, shape, and fund some of the country’s most ambitious biomedical research portfolios including at the National Institutes of Health (NIH), National Institutes of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), US Food and Drug Administration (FDA), and other government organizations. 

In the private sector, Aaron has also been a pioneer in the regulated medical cannabis industry. As partner at Missouri’s award-winning medical marijuana consulting practice A2C, state cannabis licensee, and key personnel supporting Missouri’s state constitutional amendment cannabis elections - Aaron provided comprehensive support across the lifecycle of drug legalization, implementation, and regulation. He merged US Federal-based scientific program management methodologies with the existing market for cannabis—developing compliance pathways and regulated business frameworks for cannabinoids in clinical use. His unique combination of government acumen, policy and regulatory insight, and entrepreneurial drive positions him to illuminate fenbendazole's emerging role in complementary cancer and infectious disease research via his collaborative approach to engaging government stakeholders for the benefit of the fenbendazole community. 

At the Fenbendazole Foundation, Aaron is focused on building infrastructure for responsible scientific inquiry, grant readiness, and collaborative partnerships with academic, clinical, and public health stakeholders. Having participated in Caroline’s fenbendazole social media community for over 7 years, Aaron is passionate about ensuring Caroline Williams’ vision to promote and celebrate promising compounds like fenbendazole so that they are not overlooked due to lack of institutional ownership or commercial bias.